title: Quantum-chemical approach to determining the high potency of clorgyline as an irreversible acetylenic monoamine oxidase inhibitor.
abstract: Density functional theory calculations were employed to investigate the nature of chemical bond formation between the flavin co-factor of the enzyme monoamine oxidase (MAO) and its irreversible acetylenic inhibitor clorgyline in its terminally deprotonated anionic form. Since MAOs regulate the level of neurotransmitters in living cells, this reaction is pharmacologically relevant for treating depression and other mood disorders. The results revealed that this pathway is associated with the activation free energy of ΔG act (#) = 17.4 kcal mol(-1), which, together with our previous results, suggests that clorgyline is intrinsically a more effective MAO inhibitor than antiparkinsonian drugs rasagiline and selegiline considering the preferred MAO isoforms in each case, thus displaying a trend in agreement with experimental data. The reaction is facilitated by the pronounced electrophilic character of the flavin moiety, due to its ability to efficiently accommodate excess negative charge from the approaching anionic inhibitor through resonance effect. The investigated mechanism was additionally validated by the inspection of the geometry of the flavin moiety in the formed adduct, which exhibit distortion from planarity consistent with experimental observations. These results offer valuable insight for mechanistic studies on other flavoenzymes and for the design of new antidepressants and antiparkinsonian drugs.
authors.affiliation: Laboratory for Biocomputing and Bioinformatics, National Institute of Chemistry, Hajdrihova 19, SI-1000, Ljubljana, Slovenia.
authors.forename: Matic
authors.initials: M
authors.lastname: Pavlin
authors.forename: Janez
authors.initials: J
authors.lastname: Mavri
authors.forename: Matej
authors.initials: M
authors.lastname: Repič
authors.forename: Robert
authors.initials: R
authors.lastname: Vianello
mesh_terms: D003010:Clorgyline / Q000494:pharmacology*; D039301:Computers, Molecular; D006801:Humans; D008956:Models, Chemical; D008995:Monoamine Oxidase / Q000187:drug effects* / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000737:chemistry* / Q000494:pharmacology*
chemical_list: D008996:Monoamine Oxidase Inhibitors; D008995:Monoamine Oxidase; D003010:Clorgyline
references.citation: Biochemistry. 2006 Apr 18;45(15):4775-84
references.pmid: 16605246
references.citation: J Chem Theory Comput. 2012 Oct 9;8(10):3864-70
references.pmid: 26593027
references.citation: Hum Mol Genet. 2010 Nov 1;19(21):4207-15
references.pmid: 20716577
references.citation: Brain Res. 1996 Oct 28;738(1):53-9
references.pmid: 8949927
references.citation: J Med Chem. 2005 Dec 29;48(26):8148-54
references.pmid: 16366596
references.citation: J Comput Chem. 2010 Jun;31(8):1707-14
references.pmid: 20082388
references.citation: J Neural Transm (Vienna). 2007;114(6):693-8
references.pmid: 17401536
references.citation: Biochem Pharmacol. 1982 Nov 15;31(22):3555-61
references.pmid: 6817759
references.citation: Biochemistry. 1999 Oct 12;38(41):13670-83
references.pmid: 10521274
references.citation: J Med Chem. 2011 Dec 22;54(24):8251-70
references.pmid: 22023459
references.citation: J Biol Chem. 2010 Nov 19;285(47):36849-56
references.pmid: 20855894
references.citation: J Comput Chem. 2003 Apr 30;24(6):669-81
references.pmid: 12666158
references.citation: Nat Struct Biol. 2002 Jan;9(1):22-6
references.pmid: 11753429
references.citation: J Chem Phys. 2004 Aug 22;121(8):3405-16
references.pmid: 15303903
references.citation: Eur J Biochem. 1976 Mar 16;63(1):211-21
references.pmid: 1261546
references.citation: Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12684-9
references.pmid: 16129825
references.citation: J Neural Transm (Vienna). 2013 Mar;120(3):435-44
references.pmid: 22968599
references.citation: J Neural Transm (Vienna). 2011 Jul;118(7):1031-41
references.pmid: 21190052
references.citation: Faraday Discuss. 2010;145:71-106
references.pmid: 25285029
references.citation: Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9750-5
references.pmid: 12913124
references.citation: Nat Rev Neurosci. 2006 Apr;7(4):295-309
references.pmid: 16552415
references.citation: Phys Chem Chem Phys. 2011 Jun 14;13(22):10401-11
references.pmid: 21526232
references.citation: Nature. 1972 Mar 31;236(5344):225-8
references.pmid: 4553640
references.citation: Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5739-44
references.pmid: 18391214
references.citation: J Biol Inorg Chem. 2012 Jun;17(5):687-98
references.pmid: 22434248
references.citation: J Med Chem. 2004 Mar 25;47(7):1760-6
references.pmid: 15027867
references.citation: Antioxid Redox Signal. 2009 Jul;11(7):1741-66
references.pmid: 19243237
references.citation: Br J Pharmacol. 2006 Jan;147 Suppl 1:S287-96
references.pmid: 16402116
references.citation: Stem Cells Dev. 2010 Oct;19(10):1571-8
references.pmid: 20073575
references.citation: Biochemistry. 2007 Jun 12;46(23):6892-902
references.pmid: 17511474
references.citation: Biochemistry. 1976 Jan 13;15(1):114-25
references.pmid: 2278
references.citation: Annu Rev Neurosci. 1999;22:197-217
references.pmid: 10202537
references.citation: Nature. 1970 Feb 28;225(5235):817-20
references.pmid: 5415111
references.citation: J Neural Transm (Vienna). 2012 Apr;119(4):405-14
references.pmid: 22065207
references.citation: Psychosomatics. 1985 Mar;26(3):240-6, 251
references.pmid: 3887453
references.citation: Nat Chem Biol. 2011 Oct 30;7(12):950-8
references.pmid: 22037469
references.citation: J Neural Transm (Vienna). 2011 Jul;118(7):1003-19
references.pmid: 21643793
references.citation: Chem Rev. 2003 Jun;103(6):2421-56
references.pmid: 12797836
references.citation: Org Biomol Chem. 2006 Feb 21;4(4):646-58
references.pmid: 16467939